$26.88
0.45% yesterday
Nasdaq, Dec 24, 07:00 pm CET
ISIN
US45258J1025
Symbol
IMVT

Immunovant Inc Stock price

$26.88
+3.56 15.27% 1M
+10.88 68.00% 6M
+2.11 8.52% YTD
+0.80 3.07% 1Y
+10.65 65.62% 3Y
-22.90 46.00% 5Y
+16.93 170.15% 10Y
+16.93 170.15% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
+0.12 0.45%
ISIN
US45258J1025
Symbol
IMVT
Industry

Key metrics

Basic
Market capitalization
$5.4b
Enterprise Value
$4.9b
Net debt
positive
Cash
$521.9m
Shares outstanding
174.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
10.4
Financial Health
Equity Ratio
91.1%
Return on Equity
-58.5%
ROCE
-93.7%
ROIC
-919.3%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-486.4m | $-549.0m
EBIT
$-486.8m | $-538.4m
Net Income
$-464.6m | $-522.3m
Free Cash Flow
$-431.2m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-38.1% | -25.4%
EBIT
-38.1% | -22.9%
Net Income
-43.9% | -26.2%
Free Cash Flow
-58.3%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-2.7
FCF per Share
$-2.5
Short interest
24.8%
Employees
207
Rev per Employee
$0.0
Show more

Is Immunovant Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Immunovant Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

23 Analysts have issued a Immunovant Inc forecast:

17x Buy
74%
6x Hold
26%

Analyst Opinions

23 Analysts have issued a Immunovant Inc forecast:

Buy
74%
Hold
26%

Financial data from Immunovant Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 84 84
29% 29%
-
- Research and Development Expense 404 404
41% 41%
-
-486 -486
38% 38%
-
- Depreciation and Amortization 0.42 0.42
45% 45%
-
EBIT (Operating Income) EBIT -487 -487
38% 38%
-
Net Profit -465 -465
44% 44%
-

In millions USD.

Don't miss a Thing! We will send you all news about Immunovant Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Immunovant Inc Stock News

Neutral
The Motley Fool
7 days ago
Roivant Sciences Ltd. acquired 16,666,666 shares in a single open-market purchase on Dec. 12, 2025, for a transaction value of ~$350.0 million at $21.00 per share.
Neutral
24/7 Wall Street
8 days ago
In the past week or so, secondary offerings from biotechs Immunovant Inc. (NASDAQ: IMVT), Kymera Therapeutics Inc.
Positive
Seeking Alpha
12 days ago
Immunovant (IMVT) shifts primary focus to IMVT-1402, a next-generation anti-FcRn, targeting Graves' Disease with potential best-in-class IgG reductions. I downgrade IMVT from "Strong Buy" to "Buy" due to competitive TED landscape and de-emphasis on batoclimab, despite robust upcoming catalysts. IMVT-1402 aims to address unmet needs in relapsed or uncontrolled GD patients, with pivotal data read...
More Immunovant Inc News

Company Profile

Immunovant, Inc. is a clinical-stage biopharmaceutical company. It focuses on enabling normal lives for patients with autoimmune diseases. The company was founded in 2018 and is headquartered in New York, NY.

Head office United States
CEO Eric Venker
Employees 207
Founded 2018
Website immunovant.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today